Tirofiban dosage forms and strengths

Revision as of 01:17, 7 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Tirofiban}} {{CMG}}; {{AE}} {{SS}} ==Dosage Forms and Strengths== FOR INTRAVENOUS USE ONLY AGGRASTAT Injection Premixed 5 mg tirofiban per 100 mL (50 mcg per mL)...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Tirofiban
AGGRASTAT® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Tirofiban
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Dosage Forms and Strengths

FOR INTRAVENOUS USE ONLY

AGGRASTAT Injection Premixed 5 mg tirofiban per 100 mL (50 mcg per mL) and 12.5 mg tirofiban per 250 mL (50 mcg per mL) are clear, non-preserved, sterile solutions premixed in a vehicle made iso-osmotic with sodium chloride.[1]


References

  1. "AGGRASTAT (TIROFIBAN) INJECTION, SOLUTION [MEDICURE INTERNATIONAL INC]". Retrieved 6 February 2014.

Template:WikiDoc Sources